Trials / Active Not Recruiting
Active Not RecruitingNCT04544111
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
Conditions
- Thyroid Cancer
- Thyroid Cancer, Follicular
- Papillary Thyroid Cancer
- Follicular Thyroid Cancer
- Hurthle Cell Tumor
- Poorly Differentiated Thyroid Gland Carcinoma
- Hurthle Cell Thyroid Neoplasia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trametinib | 2mg by mouth daily \*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube |
| DRUG | Dabrafenib | 150 mg twice daily (OR at dose the patient previously tolerated) |
| DRUG | PDR001 | 400mg IV every 4 weeks |
Timeline
- Start date
- 2020-09-02
- Primary completion
- 2026-09-02
- Completion
- 2026-09-02
- First posted
- 2020-09-10
- Last updated
- 2025-10-07
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04544111. Inclusion in this directory is not an endorsement.